{
    "nct_id": "NCT06567743",
    "official_title": "A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)",
    "inclusion_criteria": "• Pathologically confirmed BCG-naïve, CIS-containing (i.e., CIS with or without concomitant HG Ta/T1) high-risk NMIBC within 90 days of randomization.\n\nParticipants with BCG-naïve NMIBC should have either:\n\n* No prior treatment with BCG OR\n* No treatment with BCG within the past 24 months prior to current pathological diagnosis OR\n* A maximum of 1 or 2 doses of BCG within the past 24 months prior to current pathological diagnosis.\n* All visible disease must be resected, and all CIS resected or fulgurated, as feasible within 90 days prior to randomization.\n* Acceptable baseline organ function.\n\nCohort B Key Inclusion Criteria:\n\n* Pathologically confirmed BCG-exposed high-risk high-grade NMIBC (i.e., CIS with or without Ta/T1 disease or high-grade Ta/T1 papillary-only disease without CIS) within 90 days of treatment allocation.\n* All visible disease must be resected, and all CIS resected or fulgurated, as feasible within 90 days prior to randomization.\n* Acceptable baseline organ function.\n\nKey Exclusion Criteria (Both Cohorts):\n\n* Current or past history of muscle-invasive, locally advanced or metastatic bladder cancer.\n* High-grade disease in the upper urinary tract or prostatic urethra within 24 months of randomization or any history of muscle-invasive, locally advanced or metastatic disease in the upper urinary tract.\n* Significant immunodeficiency.\n* Pregnant or breastfeeding.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": "Cohort A Key"
}